FindTrial
Sign In

A study comparing the usefulness of Candida albicans antigen with MMR injection in skin warts.

Efficacy and safety of intralesional Candida albicans antigen versus intralesional Mumps Measles Rubella vaccine in the treatment of multiple cutaneous warts: A double blinded Randomized Controlled Trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/026098
Enrollment
50
Registered
2020-06-24
Start date
Unknown
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B07- Viral warts

Interventions

Intervention1: Candida albicans antigen - CREDISOL® aqueous allergen extract 1:1000 marketed by Creative Drug Industries, Mumbai: 0.15 ml intralesional injection into each of the two largest warts am

Sponsors

Dr JEMSHI S RAHIM
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with multiple cutaneous extragenital warts (more than 3 warts) presenting to department of Dermatology of AIIMS, Raipur, within the study period, who gives consent to participate.

Exclusion criteria

Exclusion criteria: 1.Pregnant and lactating ladies 2.Those with uncontrolled urticaria 3.Active candidiasis 4.Uncontrolled asthma 5.Known severe hypersensitivity to Candida albicans antigen or MMR vaccine 6.Acute febrile illness 7.Those receiving concomitant other treatments for warts 8.Immunosuppressed patients with Human Immunodeficiency Virus (HIV) infection, diabetes, post-splenectomy patients. 9.Patients on immunosuppressive drugs like corticosteroids 10.Past history of meningitis or convulsions 11.Patients with only oral mucosal, genital, and plane warts.

Design outcomes

Primary

MeasureTime frame
Complete cure rates with intralesional MMR and intralesional Candida albicans antigenTimepoint: 8 weeks—

Secondary

MeasureTime frame
Adverse events associated with injectionTimepoint: 0, 2, 4 and 8 weeks;Distal clearance rate with intralesional MMR Distal clearance rate with intralesional Candida albicans antigenTimepoint: 8 weeks;Rate of adverse events with intralesional MMR Rate of adverse events with intralesional Candida albicans antigenTimepoint: 8 weeks;Recurrence rate with intralesional MMR Recurrence rate with intralesional Candida albicans antigenTimepoint: 8 weeks;Time taken for complete clearance with intralesional MMR Time taken for complete clearance with intralesional Candida albicans antigenTimepoint: 2,4 and 8 weeks—

Countries

India

Contacts

Public ContactDr SATYAKI GANGULY

ALL INDIA INSTITUTE OF MEDICAL SCIENCES - RAIPUR

sjemshi@yahoo.com9074520094

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026